查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197098

HDL 膽固醇套件市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

HDL Cholesterol Kits Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，HDL 膽固醇試劑盒市場預計將以 6.2% 的複合年增長率增長。

COVID-19 大流行的出現對全球經濟和醫療保健系統產生了負面影響。 在 COVID-19 大流行期間，具有潛在風險和肥胖的人面臨更大的風險。 例如，根據疾病預防控制中心 2021 年 3 月發布的數據，所有 COVID-19 住院治療中約有 30.2% 歸因於肥胖。 在大流行期間，肥胖呈指數級增長。 例如，2021 年 8 月發表在《糖尿病、肥胖和新陳代謝》(Diabetes, Obesity and Metabolism) 上的一篇論文表明，肥胖的流行是 COVID-19 全國病例和死亡率增加的一個重要且可改變的風險因素。 COVID-19 流行病影響了市場的增長，因為它限制了醫院和診所的患者就診，並減少了進行的膽固醇測試的數量。 但是，由於解除限制和恢復服務，預計在預測期內市場將增加。

膽固醇檢測對肥胖、高脂血症和糖尿病患者的重要性日益增加，並且提高對高風險膽固醇的認識計劃預計將推動市場增長。

在過去幾十年中，肥胖症的發病率急劇上升，尤其是在發達國家和發展中國家，這些國家的生活方式疾病如焦慮、壓力、吸煙和飲酒十分普遍。它有時被稱為地方病。 肥胖也是 2 型糖尿病、心血管疾病和高血壓的重要危險因素，並且與阿爾茨海默病等腦部疾病有關。 例如，根據世界衛生組織公佈的2021年數據，估計有3820萬五歲以下兒童超重或肥胖。 隨著兒童食用更多的垃圾食品和加工食品，預計體內的維生素會減少，患上高膽固醇的風險也會增加。 因此，定期篩查膽固醇水平的需求將會增加，預計這將在預測期內推動市場增長。

同樣，根據 2022 年世界肥胖地圖集數據，預計到 2030 年印度將有 2700 萬兒童肥胖。 因此，肥胖會增加因不健康飲食、缺乏鍛煉和糖尿病等潛在疾病而患上高膽固醇的風險。 因此，在預測期內，為降低患心血管疾病風險而增加的膽固醇檢測需求預計將推動 HDL 膽固醇檢測試劑盒的增長。

此外，根據 2021 年 2 月的一篇文章，血脂異常是心血管疾病的主要危險因素。 此外，在梅克爾市的成年人口中發現血脂異常的高發率高得令人無法接受，這凸顯了在政府、非政府和公共實體的協調參與下進行早期檢測和公共衛生干預的迫切需要。 預計這將增加居民對早期檢測膽固醇的需求，以避免患上各種慢性病的風險。 因此，上述所有因素都有望推動市場增長。

但是，HDL 膽固醇檢測方法中的錯誤和不准確可能會阻礙預測期內的市場增長。

高密度脂蛋白膽固醇試劑盒市場趨勢

在預測期內，HDL 和 LDL/VLDL 檢測試劑盒部分有望主導 HDL 膽固醇試劑盒市場

高密度脂蛋白和低密度脂蛋白/極低密度脂蛋白檢測試劑盒市場的增長是由於肥胖和高脂血症患者數量的增加、心血管疾病在人群中的患病率增加、技術進步以及對膽固醇篩查和檢測方法的認識不斷提高。在預測期內，高密度脂蛋白膽固醇市場將顯著增長。

HDL 和 LDL/VLDL 檢測試劑盒提供 HDL 和 LDL/VLDL 膽固醇的定量比色測定。 脂蛋白是冠狀動脈疾病的有力預測指標。 功能性 HDL 通過去除細胞和斑塊中的膽固醇發揮保護作用。 由於動脈硬化的風險增加，高 LDL 水平和低功能性 HDL 水平與心血管疾病密切相關。 高密度脂蛋白和低密度脂蛋白之間的平衡主要由基因決定，但也可能因藥物和食物選擇等因素而改變。

根據經合組織發布的 2021 年數據，到 2030 年，預計美國約有 47% 的人口、墨西哥約有 39% 的人口和加拿大約有 35% 的人口患有肥胖症。 因此，預計肥胖人數的增加將增加對膽固醇檢測的需求，預計這將在預測期內推動細分市場的增長。

同樣，墨西哥人口中的吸煙和肥胖被發現是心髒病最常見的危險因素，這也促進了預測期內所研究市場的增長。 例如，根據世界肥胖聯合會發布的2022年統計數據，2020年墨西哥有31.5%的男性和40.2%的女性被確認患有肥胖症。

此外，不斷增長的老年人口更容易患上膽固醇和心血管疾病，推動了對膽固醇檢測試劑盒和化驗的需求，預計這將推動市場增長，從而促進市場增長。 例如，根據UNPF公佈的2022年統計數據，2022年德國15歲至64歲人口將佔總人口的64%，65歲及以上人口將佔22%。 據同一消息來源稱，在墨西哥，67%的人口年齡在15-64歲之間，8%的人口年齡在65歲以上。

此外，根據 2021 年 6 月的一篇文章，在法國，肥胖會增加患上糖尿病和高血壓等慢性疾病的可能性，並且會產生嚴重的心理和社會影響。這被認為是一個公共衛生問題。 結果，肥胖的人需要更多的血液來為他們的身體提供氧氣和營養，因此肥胖的流行增加了脂肪在動脈中堆積的風險以及發生心律失常等各種心髒病的風險增加。 因此，上述因素預計將增加對膽固醇檢測試劑盒的需求，並在預測期內推動市場增長。

北美主導市場，預計在預測期內也會如此

北美的高密度脂蛋白膽固醇有望主導市場。

肥胖、高脂血症及其相關風險的日益流行是推動市場增長的關鍵因素。 例如，根據 2021 年 1 月更新的 AHA 數據，大約 45% 的美國人口將因超重、大量吸煙和不健康的生活方式等因素而患上心髒病，而到 2035 年，心髒病發作等可能導致有關的問題

此外，該地區高昂的醫療費用也促進了市場的增長。 例如，康哲藥業2022年3月發布的數據證實，2021年至2030年國民醫療支出年均增長率為5.1%。 2020年，全國醫療保健支出為4.1萬億美元，預計2030年將達到6.8萬億美元。 因此，預計醫療保健支出的增加將增加企業活動和政府在開發技術先進的檢測設備和分析方面的舉措，從而推動對膽固醇檢測試劑盒的需求。

此外，企業在開發測試膽固醇的產品方面的活動增加也有助於市場增長。 例如，2021 年 2 月，Verichem Laboratories 推出了一種液體穩定的即用型 HDL 膽固醇驗證試劑盒，旨在校準高密度脂蛋白 (HDL) 和低密度脂蛋白 (LDL) 膽固醇測定。 這些試劑盒可滿足廣泛的臨床實驗室專業人員的需求，包括常規診斷測試、醫學研究應用以及體外診斷 (IVD) 製造和支持。 該試劑盒包含來自人血清的 HDL 和 LDL 膽固醇以及其他脂質成分，不含表面活性劑、乙二醇、疊氮化物或其他潛在干擾物質。

因此，上述所有因素預計將在預測期內推動北美市場的增長。

HDL 膽固醇試劑盒市場競爭者分析

HDL 膽固醇試劑盒市場競爭激烈，由幾家主要參與者組成。 被調查市場的主要參與者正專注於通過分銷協議和開設新的製造工廠來擴大其在亞太地區、中東和歐洲的業務。 目前主導市場的公司包括 Abbott、Randox Laboratories Ltd、Thermo Fisher Scientific、Abcam PLC、Merck KGaA、PerkinElmer Inc、Diazyme Laboratories Inc、Cell Biolabs Inc、Oscar Medicare Pvt.Ltd.。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 肥胖、高脂血症和糖尿病患者的膽固醇篩查越來越重要
    • 提高對高風險膽固醇的認識計劃
  • 市場製約因素
    • 高密度脂蛋白膽固醇測試方法的錯誤和不准確
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按產品類型
    • HDL 和 LDL/VLDL 檢測試劑盒
    • HDL 膽固醇直接試劑盒
  • 最終用戶
    • 醫院
    • 診斷機構
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • Randox Laboratories Ltd
    • Thermo Fisher Scientific
    • Abcam PLC
    • Merck KGaA
    • PerkinElmer Inc.
    • Diazyme Laboratories Inc.
    • Cell Biolabs Inc.
    • Oscar Medicare Pvt. Ltd

第7章 市場機會與今後動向

簡介目錄
Product Code: 68587

The HDL cholesterol kits market is poised to grow at a CAGR of 6.2% over the forecast period.

The emergence of the COVID-19 pandemic has had an adverse effect on the world economy and the healthcare system. People with underlying risk conditions and obesity were at greater risk during the COVID-19 pandemic. For instance, as per the data published by the CDC in March 2021, around 30.2% of the total COVID-19 hospitalizations were attributed to obesity. It was observed that obesity had increased exponentially during the pandemic. For instance, an article published in Diabetes, Obesity and Metabolism in August 2021 showed that obesity prevalence is a significant and potentially modifiable risk factor for increased COVID-19 national caseload and mortality. The COVID-19 pandemic restricted patient visits in hospitals and clinics, which decreased the number of cholesterol testing procedures and hence impacted market growth. However, with the release of restrictions and resumed services, the market is expected to increase over the forecast period.

The growing importance of cholesterol screening in obese, hyperlipidemic, and diabetic populations, as well as growing awareness programs for high-risk cholesterol, are expected to drive market growth.

The incidence of obesity has been increasing fiercely over the past decades, and it is often described as a global endemic, especially in developed and developing countries where lifestyle-related disorders, such as anxiety, stress, smoking, and drinking, are more prevalent. Also, obesity is a key risk factor for type 2 diabetes, cardiovascular disease, and hypertension, and it has also been linked to brain illnesses like Alzheimer's disease. For instance, according to the 2021 data published by the WHO, an estimated 38.2 million children under the age of 5 were overweight or obese in 2021. The increasing consumption of junk and processed foods by children decreases the number of vitamins in the body, which is expected to increase the risk of developing high cholesterol. This raises the need to routinely screen cholesterol levels, which is anticipated to propel market growth over the forecast period.

Similarly, according to World Obesity Atlas data from 2022, 27 million children in India are expected to be obese by 2030. Thus, obesity increases the risk of developing high cholesterol due to an unhealthy diet, a lack of exercise, and underlying conditions such as diabetes. This is expected to increase the demand for cholesterol testing in order to reduce the risk of developing cardiovascular disease, fueling the growth of HDL cholesterol test kits over the forecast period.

Furthermore, according to a February 2021 article, dyslipidemia is a major risk factor for cardiovascular disease. Furthermore, an unacceptably high incidence of dyslipidemia has been discovered in Mekelle City's adult population, emphasizing the critical need for early detection and public health interventions through the coordinated involvement of governmental, non-governmental, and public groups. This is expected to increase the population's need for early detection of cholesterol in order to avoid the risks of developing various chronic diseases. Therefore, all the aforementioned factors are expected to fuel market growth.

However, the errors and inaccuracies in HDL cholesterol testing methods are likely to impede the market's growth over the forecast period.

HDL Cholesterol Kits Market Trends

HDL and LDL/VLDL Assay Kit Segment is Expected to Dominate the HDL Cholesterol Kits Market Over the Forecast Period

The HDL and LDL/VLDL assay kit segment is expected to grow significantly in the HDL cholesterol market over the forecast period due to an increase in obesity and hyperlipidemia cases, an increase in the prevalence of cardiovascular diseases among the population, technological advancements, and increased awareness about cholesterol screening and testing procedures.

The HDL and LDL/VLDL assay kit is a quantitative colorimetric determination of HDL and LDL/VLDL cholesterol. Lipoproteins are strong predictors of coronary heart disease. Functional HDL offers protection by removing cholesterol from cells and atheroma. Higher concentrations of LDL and lower concentrations of functional HDL are strongly associated with cardiovascular disease due to a higher risk of atherosclerosis. The balances between high and low-density lipoproteins are solely genetically determined but can be changed by medications, food choices, and other factors.

According to the 2021 data published by the OECD, about 47% of the population in the United States, 39% in Mexico, and 35% in Canada are expected to suffer from obesity by 2030. As a result, the expected high number of obese people raises the demand for cholesterol testing, which is expected to drive segment growth over the forecast period.

Similarly, smoking and obesity in the Mexican population are found to be the most prevalent heart disease risk factors, which are also contributing to the growth of the market studied over the forecast period. For instance, according to 2022 statistics published by the World Obesity Federation, it has been observed that 31.5% of men and 40.2% of women were living with obesity in Mexico in 2020.

Furthermore, the growing geriatric population is contributing to market growth because they are more likely to develop cholesterol and cardiovascular diseases, which is expected to fuel demand for cholesterol testing kits and assays, boosting market growth. For instance, according to the 2022 statistics published by the UNPF, in 2022, in Germany, a large proportion is aged 15-64 and accounts for 64% of the population, while 22% of the population is aged 65 years and above. Also, as per the same source, in Mexico, a large proportion of the living population is aged 15-64 and accounts for 67% of the population, while 8% of the population is aged 65 years and above.

Furthermore, according to a June 2021 article, obesity is considered a serious public health issue in France because it increases the likelihood of developing chronic conditions such as diabetes, hypertension, and other conditions with severe psychological and social consequences. As a result, the prevalence of obesity raises the risk of developing a variety of heart ailments, such as fatty buildup in the arteries, irregular heartbeats, and other issues, because obese people require more blood to provide oxygen and nutrition to the body. Thus, the aforesaid factors are expected to increase demand for cholesterol testing kits, which is anticipated to propel market growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the HDL cholesterol market over the forecast period due to factors such as rising obesity and hyperlipidemia rates among the population, increasing technological advancements in cholesterol detection products, the presence of well-established healthcare infrastructure, and the region's high healthcare expenditure.

The increasing prevalence of obesity, hyperlipidemia, and associated risks is the key factor driving market growth. For instance, according to the AHA data updated in January 2021, around 45% of the United States population is likely to suffer from heart disease due to factors like high obesity, high smoking, and unhealthy lifestyles, which may lead to heart attacks and other related issues by 2035.

In addition, the high healthcare expenditure in the region is also contributing to market growth. For instance, as per the data published by the CMS in March 2022, it has been observed that the annual growth in national health spending is expected to be an average of 5.1% over 2021-2030. Also, the national health spending in 2020 was USD 4.1 trillion, and it was projected to reach USD 6.8 trillion by 2030. Thus, the increasing healthcare spending is expected to increase company activities and government initiatives in developing technologically advanced testing devices and assays, thereby propelling the demand for cholesterol testing kits.

Furthermore, the rising company activities in developing products for testing cholesterol also contribute to the market's growth. For instance, in February 2021, Verichem Laboratories launched a liquid-stable and ready-to-use HDL Cholesterol Verifier Kit intended to calibrate both High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) cholesterol assays. The kit meets the needs of a wide variety of clinical laboratory professionals, including those involved in routine diagnostic testing, medical research applications, and the manufacturing and support of in-vitro diagnostic (IVD) products. The kit contains HDL and LDL cholesterol and other lipid components from human serum free of surfactants, glycols, azide, and other potential interfering substances.

Thus, all the aforementioned factors are expected to propel market growth in North America over the forecast period.

HDL Cholesterol Kits Market Competitor Analysis

The HDL cholesterol kit market is moderately competitive and consists of several major players. The major players in the market studied are focusing on expanding their presence in the Asia-Pacific, the Middle East, and Europe through distribution agreements and the opening of new manufacturing facilities. Some of the companies that are currently dominating the market are Abbott, Randox Laboratories Ltd, Thermo Fisher Scientific, Abcam PLC, Merck KGaA, PerkinElmer Inc., Diazyme Laboratories Inc., Cell Biolabs Inc., and Oscar Medicare Pvt. Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Importance of Cholesterol Screening in the Obese, Hyperlipidemic, and Diabetic Population
    • 4.2.2 Growing Awareness Programs for High-Risk Cholesterol
  • 4.3 Market Restraints
    • 4.3.1 Errors and Inaccuracy in HDL Cholesterol Testing Methods
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 HDL and LDL/VLDL Assay Kit
    • 5.1.2 HDL Cholesterol Direct Reagent Kit
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Randox Laboratories Ltd
    • 6.1.3 Thermo Fisher Scientific
    • 6.1.4 Abcam PLC
    • 6.1.5 Merck KGaA
    • 6.1.6 PerkinElmer Inc.
    • 6.1.7 Diazyme Laboratories Inc.
    • 6.1.8 Cell Biolabs Inc.
    • 6.1.9 Oscar Medicare Pvt. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS